Core Viewpoint - UBS reports that six new products from Innovent Biologics and the new indications for Sintilimab have been included in the updated National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) [1] Group 1: Product Impact - UBS predicts that sales of the new products (IGF-1R, EGFR, BTK, ROS1, KRAS G12C, RET) will experience rapid growth by 2026 [1] - The inclusion of Teriparatide for diabetes indications in the insurance scheme positively impacts the market outlook for Masitinib, which is expected to launch in 2026 [1] Group 2: Market Position - Being included in the Hang Seng Index is expected to enhance the liquidity of the stock [1] - UBS sets a target price of HKD 137.4 for Innovent Biologics, maintaining a "Buy" rating [1]
大行评级丨瑞银：预测信达生物新产品销售明年快速增长 评级“买入”